Chamber-specific contractile responses of atrial and ventricular hiPSC-cardiomyocytes to GPCR and ion channel targeting compounds: A microphysiological system for cardiac drug development.

Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) have found utility for conducting in vitro drug screening and disease modelling to gain crucial insights into pharmacology or disease phenotype. However, diseases such as atrial fibrillation, affecting >33 M people worldwide, demonstrate the need for cardiac subtype-specific cells. Here, we sought to investigate the base characteristics and pharmacological differences between commercially available chamber-specific atrial or ventricular hiPSC-CMs seeded onto ultra-thin, flexible PDMS membranes to simultaneously measure contractility in a 96 multi-well format. We investigated the effects of GPCR agonists (acetylcholine and carbachol), a Ca ²⁺ channel agonist (S-Bay K8644), an HCN channel antagonist (ivabradine) and K ⁺ channel antagonists (4-AP and vernakalant). We observed differential effects between atrial and ventricular hiPSC-CMs on contractile properties including beat rate, beat duration, contractile force and evidence of arrhythmias at a range of concentrations. As an excerpt of the compound analysis, S-Bay K8644 treatment showed an induced concentration-dependent transient increase in beat duration of atrial hiPSC-CMs, whereas ventricular cells showed a physiological increase in beat rate over time. Carbachol treatment produced marked effects on atrial cells, such as increased beat duration alongside a decrease in beat rate over time, but only minimal effects on ventricular cardiomyocytes. In the context of this chamber-specific pharmacology, we not only add to contractile characterization of hiPSC-CMs but propose a multi-well platform for medium-throughput early compound screening. Overall, these insights illustrate the key pharmacological differences between chamber-specific cardiomyocytes and their application on a multi-well contractility platform to gain insights for in vitro cardiac liability studies and disease modelling.
Competing Interests: Declaration of competing interest Authors Bettina Lickiss, Matthias Gossmann, Jan Hunker and Peter Linder are employed by innoVitro GmbH, the manufacturer of the FLEXcyte 96 consumables and co-developer of the FLEXcyte 96 used to compile this manuscript. Authors Ulrich Thomas, Elena Dragicevic and Sonja Stoelzle-Feix are employed by Nanion Technologies GmbH, the manufacturer of the FLEXcyte 96 used to compile this manuscript. Authors Jamie Bhagwan, Hardeep Lotay, Steven Broadbent and Jan Turner are employed by Axol Bioscience Ltd., the manufacturer of axoCells™ Ventricular and Atrial Cardiomyocytes used in this study.
(Copyright © 2024 Elsevier Inc. All rights reserved.)